Table 3.
Top 20 differentially expressed mRNAs in endometrial adenocarcinoma with lymphovascular space involvement (LVSI) compared to expression in the LVSI-LN- group without metastasis.
| Gene name | Log2 fold change | P-value | Gene sets |
|---|---|---|---|
| BIRC5 | 1.95 | 0.000298 | Apoptosis, Cell Proliferation |
| COMP | 3.86 | 0.000402 | Matrix Remodeling and Metastasis, PI3K-Akt |
| CENPF | 1.97 | 0.000546 | Cell Proliferation |
| AXIN1 | 0.687 | 0.000639 | Wnt Signaling |
| CCL3/L1 | 1.31 | 0.00137 | Cytokine and Chemokine Signaling |
| GMIP | 0.65 | 0.00143 | – |
| CDC20 | 1.33 | 0.00145 | Antigen Presentation, Cell Proliferation |
| CCNE1 | 1.67 | 0.00153 | Angiogenesis, Cell Proliferation, Metabolic Stress, PI3K-Akt |
| CCNB1 | 1.21 | 0.00158 | Cell Proliferation |
| EZH2 | 1.05 | 0.00165 | Angiogenesis, Epigenetic Regulation, Metabolic Stress |
| IL21R | 2 | 0.00205 | Cytokine and Chemokine Signaling, JAK-STAT Signaling |
| MELK | 1.25 | 0.00207 | Cell Proliferation |
| BLM | 1.14 | 0.00222 | Apoptosis, Cell Proliferation, DNA Damage Repair |
| FANCA | 1.49 | 0.00268 | DNA Damage Repair |
| H2AFX | 1.14 | 0.00292 | Cell Proliferation, DNA Damage Repair, Epigenetic Regulation, Metabolic Stress |
| CCL18 | 1.83 | 0.00295 | Cytokine and Chemokine Signaling |
| BRCA2 | 1.23 | 0.00323 | Cell Proliferation, DNA Damage Repair |
| VEGFB | 0.492 | 0.00352 | Angiogenesis, MAPK, PI3K-Akt |
| BRCA1 | 0.833 | 0.00356 | Cell Proliferation, DNA Damage Repair, PI3K-Akt |
| RRM2 | 0.957 | 0.00376 | Cell Proliferation |
LVSI, lymphovascular space involvement; LN, lymph node.